Sign In
Buy JNJ
$239.08
+7.79 (+3.37%)
At Close: Jun 23, 2026
Patients treated with subcutaneous TREMFYA® achieved clinically meaningful results in both clinical remission (36.7%) and endoscopic remission (25.9%) at Week 48 in the Phase 3 ASTRO study Clinical a
Studies presented at #Academy25 reveal that ACUVUE OASYS MAX 1-Day for ASTIGMATISM outperformed Dailies Total1® for Astigmatism in patient reported outcomes related to vision and comfort. Research h
Johnson & Johnson to Participate in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference
04:00pm, Monday, 06'th Oct 2025
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on Tuesday, November 11th, 2025. Management wi
Trump's Drug Price Cuts: Boom or Bust for These 3 Pharma Giants
02:21pm, Monday, 06'th Oct 2025
When investors hear that a company will lower prices on its products, their instinctive reaction is to expect a sequential decline in margins and profits, which is not entirely incorrect. However, som
My Top 5 Biotech Stocks Big Pharma Could Buy Next
01:29pm, Monday, 06'th Oct 2025
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of
How J&J's Innovative Medicines Segment is Poised Ahead of Q3 Results
09:37am, Monday, 06'th Oct 2025
JNJ's Innovative Medicine sales face biosimilar pressure and IRA headwinds, but growth drivers like Darzalex, Tremfya and Erleada may have ensured steady Q3 momentum.
5 Dividend Kings Are Our Top High-Yield Dividend Picks For October
06:33am, Monday, 06'th Oct 2025
Investors love dividend stocks, especially those with high yields, because they provide a substantial income stream and offer significant total return potential.
October Dogs Of The Dow Flash One Ideal 'Safer' Dividend Buy
12:18pm, Saturday, 04'th Oct 2025
Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price. Analyst forecasts suggest top-ten Dow Dogs could deliver average net
Johnson & Johnson (JNJ) Rises Higher Than Market: Key Facts
06:46pm, Friday, 03'rd Oct 2025
Johnson & Johnson (JNJ) closed the most recent trading day at $188.64, moving +1.43% from the previous trading session.
Examining JNJ Breakout: Bull Flag & Options Show Upside Potential
04:00pm, Friday, 03'rd Oct 2025
Johnson & Johnson (JNJ) has shined in the healthcare space, rallying 5% this week and 30% in 2025. An upgrade from Wells Fargo added momentum to the stock rally on Friday.
2 Dividend Stocks That Jim Cramer Wants Every Retiree to Own
09:11am, Friday, 03'rd Oct 2025
Retirees and older individuals are among the biggest demographics who tune into Jim Cramer's Mad Money show.
The 5 Highest-Yielding Dogs of the Dow Are Among Our Top Q4 Picks
03:15pm, Thursday, 02'nd Oct 2025
The Dogs of the Dow is a well-known strategy first published in 1991 by Michael O'Higgins.
NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer
04:15pm, Wednesday, 01'st Oct 2025
Data presented at the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO) on October 1 st
Why JNJ Stock Defines Shareholder Supremacy In Healthcare
09:45am, Tuesday, 30'th Sep 2025
Over the past ten years, Johnson & Johnson (NYSE: JNJ) has delivered an impressive $157 Bil back to its investors through cash distributions via dividends and buybacks. This commitment to shareholder
3 Ultra-Safe Dividend Stocks to Buy Now, If You're Concerned About Volatility Ahead
08:41am, Tuesday, 30'th Sep 2025
Investors who find themselves awake at night thinking about their portfolios, fear not.
